The efficacy and safety of Pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160 mg/dl

American Journal of Cardiology

Volumn 77, Issue 1, 1996, Pages 83-85

  Glasser, Stephen P ^a   DiBianco, Robert ^a   Effron, Barry A ^a   Faas, Fred ^a   Germino, F Wilford ^a   Shane, Louis E ^a   Unger, Allen H ^a   Staggers, Joan E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRAVASTATIN; TREATMENT OUTCOME;

EID: 0030034966     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89140-0     Document Type: Article

References (6)

1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
2. Mellies MJ, DeVault AR, Kassler-Taub K, McGovern ME, Pan HY. Pravastatin experience in elderly and non-elderly patients. Atherosclerosis 1993;101:97-110.
3. Santinga JT, Rosman HS, Rubenfire M, Maciejko JJ, Kobylak L, McGovern ME, Behounek BD. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med 1994;96:509-515.
4. LaRosa JC, Applegate W, Crouse JR, Hunninghake DB, Grimm R, Knopp R, Eckfeld JH, Davis CE, Gordon DJ. Cholesterol lowering in the elderly: results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med 1994;154:529.
5. Ashraf T, Hay JW, Crouse JR, Davidson MH, Furberg CD, Pitt B, Wittels EH. The cost-effectiveness of pravastatin in secondary prevention of coronary heart disease (abstr). J Am Coll Cardiol 1995;25:390A.
6. Furberg CD, Pitt B, Byington RP, Park JS, McGovern ME. Reduction in coronary events during treatment with pravastatin. Am J Cardiol 1995;76:60C-63C.